Ciaran J. McMullan

机构：Merck & Co., Inc., Rahway, NJ, USA (United States) · ORCID：0000-0001-7269-6391

发表论文 121 篇 · 总被引 6087 次 · h-index 32

代表论文

• Vericiguat in patients with chronic heart failure and reduced ejection fraction (VICTOR): a double-blind, placebo-controlled, randomised, phase 3 trial (2025 · The Lancet · 被引 82)
• Vericiguat for patients with heart failure and reduced ejection fraction across the risk spectrum: an individual participant data analysis of the VICTORIA and VICTOR trials (2025 · The Lancet · 被引 45)
• Vericiguat Global Study in Participants with Chronic Heart Failure: Design of the VICTOR Trial (2024 · European Journal of Heart Failure · 被引 38)
• Baseline Characteristics of Contemporary Trial Participants with Heart Failure and Reduced Ejection Fraction: The VICTOR Trial (2025 · European Journal of Heart Failure · 被引 22)
• Vericiguat and mortality in heart failure and reduced ejection fraction: the VICTOR trial (2025 · European Heart Journal · 被引 21)
• Effect of Vericiguat on Total Heart Failure Events in Compensated Outpatients With HFrEF (2025 · Journal of the American College of Cardiology · 被引 20)